New PI3K-delta Inhibitor Prolongs Survival in Chronic Lymphocytic Leukaemia

New PI3K-delta Inhibitor Prolongs Survival in Chronic Lymphocytic Leukaemia

Lots of good's ASCO time...

The substantial clinical activity of idelalisib that we observed justifies its further clinical development in CLL,” said Jennifer R. Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia center at Dana-Farber Cancer Institute in Massachusetts and lead author of the study.

Last edited by

2 Replies

  • My husband has been involved in the trial of this drug combined with Rituximab. He has been involved with the trial since the 11th December 2012. His improvement was noticeable within a few weeks of starting the trial and has continued to improve. His counts are now all normal and his lymph nodes have reduced by 75% and his spleen has reduced in size. It was a blind trial so we still do not know whether he had the placebo or the drug but the results would suggest that he had the drug. He will continue to receive the placebo or the drug twice a day and he will be monitored on a six weekly basis. If his condition deteriorates then we will find out whether he has had the drug or the placebo. If he has received the placebo then he will be given the drug, alternatively if he has received the drug then they will increase the dosage. We are enjoying the current improvement and hope that it will continue.

  • Hi the more treatments/drugs the better.

You may also like...